These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 14682185)

  • 1. [Bone remodeling].
    Cohen-Solal M; de Vernejoul MC
    Therapie; 2003; 58(5):391-3. PubMed ID: 14682185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new targets for therapy of osteolytic bone disease in multiple myeloma.
    Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
    Curr Drug Targets; 2005 Sep; 6(6):701-11. PubMed ID: 16178802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?
    Coetzee M; Kruger MC
    South Med J; 2004 May; 97(5):506-11. PubMed ID: 15180028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
    Kostenuik PJ; Shalhoub V
    Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights in myeloma-induced osteolysis.
    Barillé-Nion S; Bataille R
    Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone remodeling and mineral homeostasis].
    Nakamura M; Udagawa N; Nakamura H
    Clin Calcium; 2006 Jan; 16(1):46-53. PubMed ID: 16397350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?].
    Neumann E
    Z Rheumatol; 2006 Sep; 65(5):400, 402-6. PubMed ID: 16924451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
    Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
    Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
    Ueland T; Bollerslev J; Mosekilde L
    Ugeskr Laeger; 2002 Jul; 164(27):3526-30. PubMed ID: 12116680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone remodeling.
    Hadjidakis DJ; Androulakis II
    Ann N Y Acad Sci; 2006 Dec; 1092():385-96. PubMed ID: 17308163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [RANKL and OPG regulation on bone remodeling].
    Zhao Y; Cai Y; Wang YN
    Shanghai Kou Qiang Yi Xue; 2010 Aug; 19(4):443-6. PubMed ID: 20871967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE; Mylchreest S; Andrew JG
    BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The participation of RANK, RANKL and OPG in tumor osteolysis].
    Stanisławowski M; Kmieć Z
    Postepy Hig Med Dosw (Online); 2009 May; 63():234-41. PubMed ID: 19502684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel molecular mechanism modulating osteoclast differentiation and function.
    Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
    Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of bone cell development and function: implication for renal osteodystrophy.
    Disthabanchong S; González EA
    J Investig Med; 2001 May; 49(3):240-9. PubMed ID: 11352181
    [No Abstract]   [Full Text] [Related]  

  • 20. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
    Suda T; Takahashi N; Udagawa N; Jimi E; Gillespie MT; Martin TJ
    Endocr Rev; 1999 Jun; 20(3):345-57. PubMed ID: 10368775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.